ORIGINAL ARTICLE

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations

Marta Futema,1 Vincent Plagnol,2 KaWah Li,1 Ros A Whitall,1 H Andrew W Neil,3 Mary Seed,4 on behalf of the Simon Broome Consortium, Stefano Bertolini,5 Sebastiano Calandra,6 Olivier S Descamps,7 Colin A Graham,8 Robert A Hegele,9 Fredrik Karpe,10 Ronen Durst,11,12 Eran Leitersdorf,12 Nicholas Lench,13 Devaki R Nair,14 Handrean Soran,15 Frank M Van Bockxmeer,16 UK10K Consortium,17 Steve E Humphries1

ABSTRACT

Background Familial hypercholesterolaemia (FH) is an autosomal dominant disease of lipid metabolism, which leads to early coronary heart disease. Mutations in LDLR, APOB and PCSK9 can be detected in 80% of definite FH (DFH) patients. This study aimed to identify novel FH-causing genetic variants in patients with no detectable mutation.

Methods and results Exomes of 125 unrelated DFH patients were sequenced, as part of the UK10K project. First, analysis of known FH genes identified 23 LDLR and two APOB mutations, and patients with explained causes of FH were excluded from further analysis. Second, common and rare variants in genes associated with low-density lipoprotein cholesterol (LDL-C) levels in genome-wide association study (GWAS) meta-analysis were examined. There was no clear rare variant association in LDL-C GWAS hits; however, there were 29 patients with a high LDL-C SNP score suggestive of polygenic hypercholesterolaemia. Finally, a gene-based burden test for an excess of rare (frequency <0.005) or novel variants in cases versus 1926 controls was performed, with variants with an unlikely functional effect (intronic, synonymous) filtered out.

Conclusions No major nolcus for FH was detected, with no gene having a functional variant in more than three patients; however, an excess of novel variants was found in 18 genes, of which the strongest candidates included CH25H and INSIG2 (p<4.3×10−4 and p<3.7×10−3, respectively). This suggests that the genetic cause of FH in these unexplained cases is likely to be very heterogeneous, which complicates the diagnostic and novel gene discovery process.

INTRODUCTION

Familial hypercholesterolaemia (FH (OMIM #143890)) is a genetic disorder, inherited in an autosomal dominant fashion, characterised by the defective plasma clearance of low-density lipoprotein cholesterol (LDL-C) and caused by mutations in three genes: LDLR, APOB and PCSK9. A recessive form of FH due to mutations in LDLRAP1 is also known. FH is estimated to affect one in 500 individuals and if untreated leads to premature coronary heart disease (CHD). In the UK, the FH Simon Broome criteria are used for the diagnosis, which classify patients into possible FH, when adults present with total cholesterol >7.5 mmol/L or LDL-C >4.9 mmol/L, and family history of high cholesterol or premature CHD, or the more severe form—definite FH (DFH), when in addition to the above, tendon xanthomas are present in the patient or first or second degree relative. The FH mutation detection rate for DFH patients varies between 63% and 87%, suggesting that there are other genetic causes, located outside of the currently screened regions, which are yet to be identified. The importance of identifying an FH-causing variant, which has clinical utility in providing an unequivocal diagnosis, has been emphasised by the National Institute of Health and Care Excellence, which in 2008 recommended cascade testing using DNA information for finding the affected relatives of a patient. The risk of early CHD can be significantly reduced by statin treatment, and genetic information has been demonstrated to complement the management of treated patients.

OF FH patients where a mutation can be found, ~93% occur in the LDLR gene. The APOB variant (c.10580G>A, p.(Arg3527Gln)) accounts for ~5% of UK FH cases, whereas a gain-of-function mutation in PCSK9 (c.1120G>T, p.(Asp374Tyr)) can be found in roughly 1.7% of FH patients. In the past few years, several loci have been reported to cosegregate with FH in family linkage studies; however, to date, this has not led to the identification of a specific causal gene. It is likely that there are novel FH mutations located in unknown genes influencing lipid metabolism and that their discovery may contribute to the identification of novel treatment targets. In order to find novel causes of FH it was agreed that, as part of the UK10K project (http://www.uk10k.org/studies/rarediseases.html), the whole exomes of 125 unrelated DFH patients were sequenced at a high depth. We expected that an FH-causing mutation in a novel gene would be very rare accounting for fewer FH cases than the gain-of-function mutation in PCSK9 (1.7%), since a higher frequency would have made likely its identification in previous studies. We also suspected that a proportion of
patients would have polygenic hypercholesterolaemia, due to the combined impact of common LDL-C-raising SNPs.\(^\text{18}\)

**MATERIALS AND METHODS**

**Patients**

A total of 125 unrelated patients, diagnosed as DFH using the UK Simon Broome criteria on the basis of the presence or family history of tendon xanthomas, were initially screened and shown to be negative for mutations in known FH genes (LDLR, APOB, PCSK9 and LDLRAP1). All consents and local review board approvals were in accordance with the UK10K project ethical framework. The initial mutation screening methods varied and are summarised in online supplementary table S1.

**Controls**

The association with FH was tested against consented 1926 UK10K samples with no lipid abnormalities (listed in online supplementary methods), sequenced in parallel, using the same sequence capture and variant calling methods (http://www.uk10k.org/studies/).

**Exome sequencing and variant calling**

The whole exome sequencing was performed and processed at the Wellcome Trust Sanger Institute (Cambridge, UK) as part of the UK10K project (see online supplementary methods). CNVs were called using the ExomeDepth package for R (freely available at the Comprehensive R Archive Network).\(^\text{19}\)

**Filtering of the variants**

Variants were flagged as rare (frequency<0.5%) and novel (frequency=0) according to their frequency in publicly available databases including 1000 Genomes\(^\text{20}\) and National Heart, Lung, and Blood Institute (NHHLBI) Exome Sequencing Project (ESP6500) (http://evs.gs.washington.edu/EVS/). In addition to the frequency filters, a functional flag was added, which prioritised variants that are most likely to affect a protein’s function, which is, non-synonymous, stop gain, stop loss, frameshift deletions and insertions, and splice site variants.

**Burden test for association**

Rare or novel variants were combined in a single gene manner and counted in cases versus 1926 controls (i.e., gene by gene). A binomial test was used to assess the excess of functional rare and novel variants in cases in comparison with the controls. p Values lower than \(4\times10^{-3}\) were taken as evidence sufficient to be flagged for follow-up.

**Analysis of the variants**

Variants within Tier 1 genes (LDLR, APOB, PCSK9, LDLRAP1) were assessed on the basis of their frequency, and manually by looking at their annotations in the UCL FH mutation database.\(^\text{21}\) Sanger sequencing was used to confirm all called mutations. Samples with known FH mutations and therefore an explained cause were removed from further analysis.

The Tier 2 list (see online supplementary table S2) consisted of genes associated with LDL-C as a lead trait in the largest (at the time) available Global Lipid Genetic Consortium (GLGC) meta-analysis of genome-wide association studies (GWAS).\(^\text{22}\) Functional rare and novel variants in the Tier 2 genes were compared by the burden test against non-FH controls, as one group (counts in all genes combined) and by each single gene.

**LDL-C gene score analysis**

The possibility of polygenic hypercholesterolaemia in this cohort was assessed using the LDL-C gene score analysis, recently described.\(^\text{18}\) Most of the 12 LDL-raising GWAS SNPs are located outside of the coding regions, and thus to obtain these genotypes, methods as in the original publication were used.\(^\text{18}\) Gene scores were calculated by summing the weights of LDL-raising alleles provided by the GLGC (see online supplementary table S3) and the APOE haplotype was scored as follows: \(\epsilon_2\epsilon_2=-0.9, \epsilon_2\epsilon_3=-0.4, \epsilon_2\epsilon_4=-0.2, \epsilon_3\epsilon_3=0, \epsilon_3\epsilon_4=0.1\) and \(\epsilon_4\epsilon_4=0.2.\)\(^\text{22}\) Gene scores of a randomly selected subjects from the UK Whitehall II (WHII) study (n=3020) were used as a healthy control comparison group.\(^\text{23}\) Individuals with a gene score above 1.16, which was the top decile cut-off for the WHII subjects, were considered to have polygenic hypercholesterolaemia. The Welch two sample t test was used to test for an overall difference between the groups.

**RESULTS**

We first analysed variants in known FH genes (figure 1A) (for gene coverage see online supplementary results). For LDLR, 10 individuals were carrying a missense mutation, five a nonsense mutation, three had small deletions and two individuals had intronic changes known to affect splicing (see online supplementary table S4). Analysis with ExomeDepth for CNVs identified two large duplications and one deletion within the LDLR region (see online supplementary figure S1). For APOB, two individuals carried the known FH mutation, c.10580G>A (p.R3527Q), and several novel and cases-unique APOB variants, distributed across different gene exons, were identified (see online supplementary table S5). These included a recently identified mutation, p.R505W, which cosegregated with the disease.\(^\text{24}\) Because APOB is highly polymorphic, the overall number of rare variants was not significantly different in comparison with controls. PCSK9 had the lowest mean read depth (18X), with four exons (1, 5, 9 and 10) covered less than 10X due to a high guanine and/or cytosine (GC) content (see online supplementary figure S2). There were no FH-causing variants identified in this gene. There were no homozygous or compound heterozygous calls in the LDLRAP1 gene in any of the samples. One patient was found to be heterozygous for a previously identified frameshift mutation (c.432_433insA (p.(Ala145LysfsX26))).\(^\text{25}\)

**LDL-C gene score analysis**

Out of 109 FH samples (21 mutation positive, 88 mutation negative) with sufficient DNA for genotyping for all 12 SNPs, 31 had a gene score above the 1.16 cut-off (figure 1A), within which two samples, in addition to the high gene score, had an LDLR mutation, one in exon 11 (c.1690A>C (p.N564H)) found on the same allele as a 9bp deletion in exon 17 (c.2393_2401del9 (p.L799_V801del)), which has been demonstrated as not fully penetrant.\(^\text{26}\) The other was a deletion of a consensus splice site at the 5’ of exon 5, c.695-6_698del, which has not been examined in vivo to confirm its likely effect on splicing.

The mean LDL-C gene score for the FH mutation negative group was 1.08, which was significantly higher than 0.90 for the WHII study (p<2.2×10\(^{-16}\)) and 0.96 for the FH mutation positive group (p=0.006) (figure 1B) (for the distribution of scores see online supplementary figure S3). The overall difference between the groups was significant (analysis of variance (ANOVA), p=1.33×10\(^{-12}\)). Individuals with a gene score above the top decile cut-off for the WHII subjects (>1.16), were
considered to have polygenic hypercholesterolaemia and excluded from further analysis as they were unlikely to carry a single mutation of a strong effect.

**GWAS LDL-C genes**

We next examined any gene identified through GWAS as being involved in determining levels of LDL-C in healthy individuals.22 A burden test on all functional rare and novel variants in any gene singly or in all Tier 2 genes combined showed no obvious candidate for a novel FH locus (see online supplementary table S6). In addition, there were no loss-of-function variants (ie, premature stop codon formation, loss of a stop codon, frameshift indels, CNVs) observed in these genes in any sample (n=125), or in the 71 with no identified mutation and a low gene score. There was no association of novel functional variants in any gene located within the several loci identified by published family linkage studies (see online supplementary table S7).

**Whole exome analysis**

In all, 25 samples carrying a mutation in Tier 1 genes and 29 with the LDL-C gene score above 1.16 were removed from further analysis. To interrogate the whole exome, a burden test was performed between 71 cases and 1926 controls. There were 4407 genes with one or more novel functional variant in cases. In order to remove calls less likely to influence the FH phenotype and increase the power of the test, we limited further analysis only to genes where a maximum of four novel functional variants were seen in the controls, based on the expected prevalence of FH of 1 in 500, and therefore any gene with >4 novel functional variants in the controls were excluded (the original gene list is shown in online supplementary table S8). Variants in genes located on the X chromosome were removed from the final list (X chromosome genes shown in online supplementary table S8). The next step involved a visual validation of the quality of calls performed using the Human Genome 19 on the Integrative Genomic Viewer (IGV).27 In order to avoid false negatives, calls that were filtered out due to inadequate quality were reanalysed in genes showing excess of novel variants. An additional loss-of-function variant, a premature stop codon at the position c.244C>T (p.Q81*), was found in the CH25H gene in an FH patient sample with a low LDL-C SNP score. After adjusting for the false positives and false negatives,

---

**Figure 1** Novel familial hypercholesterolaemia (FH) gene discovery pipeline. (A) To increase the chance of detecting true FH-causing variants with a strong effect and reduce the noise, samples with a mutation in LDLR or APOB (apart from novel APOB variants of unknown effect) or those with a high low-density lipoprotein cholesterol (LDL-C) gene score were removed from the analysis. The remaining variants were filtered by their frequency and functional effect and compared against controls. Genes with more than four novel functional variants in controls or genes located on the X chromosome were filtered out to enhance the power of the test. The remaining variants were manually assessed and false positive calls were removed. (B) Comparison of the LDL-C SNPs score among the WHII control population (n=3020), FH mutation positive individuals (n=21) and FH mutation negative individuals (n=83) in a standard boxplot (the minimum, lower quartile, median, upper quartile and maximum). The overall difference between the groups was highly significant (ANOVA, p<2.2×10^{-16}). Dashed line indicates the top decile cut-off for the WHII cohort (=1.16). A gene score was not attainable for 16 samples due to a poor DNA quality and insufficient concentration, which resulted in incomplete genotype data. (C) Schematic representation of the intronless CH25H gene and the localisation of novel variants identified in the FH cohort (in boxes). CH25H encodes an enzyme, cholesterol 25-hydroxylase, known to be spanning the endoplasmic reticulum membrane, with two domains (including the N-terminal) located outside of the membrane (in light grey), three 20 amino acid long transmembrane regions and two domains positioned inside the membrane, which contain three His boxes, essential for the catalytic activity of the enzyme.30

### Table 1  Summary of genes and their variants which show an excess of novel functional variants in FH cases (n=71) in comparison with controls (n=1926)

<table>
<thead>
<tr>
<th>Gene</th>
<th>Ch</th>
<th>Number of variants in cases (n=71)</th>
<th>Number of variants in controls (n=1926)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH25H</td>
<td>10</td>
<td>3</td>
<td>2</td>
<td>4.3×10^{-4}</td>
</tr>
<tr>
<td>HSPB7</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>1.3×10^{-3}</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ENST0000371852:exon1:c.T742G:p.A199+7G&gt;A</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>KLRC1</td>
<td>12</td>
<td>2</td>
<td>0</td>
<td>1.3×10^{-3}</td>
</tr>
<tr>
<td>MOAP1</td>
<td>14</td>
<td>3</td>
<td>4</td>
<td>1.4×10^{-3}</td>
</tr>
<tr>
<td>RBM25</td>
<td>14</td>
<td>3</td>
<td>4</td>
<td>1.4×10^{-3}</td>
</tr>
<tr>
<td>ANP32E</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>CABPS</td>
<td>19</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>CELA2B</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>INSI2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>KCTD7</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>MRO</td>
<td>18</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>NR2E1</td>
<td>6</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>PABPC1</td>
<td>8</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>PODXL</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>PUS3</td>
<td>11</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>TXNDC15</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>WDR89</td>
<td>14</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
<tr>
<td>ZNF720</td>
<td>16</td>
<td>2</td>
<td>1</td>
<td>3.7×10^{-3}</td>
</tr>
</tbody>
</table>

Ch, chromosome; FH, familial hypercholesterolaemia.


Complex traits
CH25H remained the top gene (p=4.3×10^{−4}) with three variants in the cases and two in the controls (table 1). To examine the prevalence of nonsense variants in CH25H in public data sources, we analysed the NHLBI ESP database and found one nonsense allele (c.638delT) in 6503 individuals (Minor Allele Frequency (MAF)=0.00008), which was significantly lower than in the FH group (MAF=0.0003, p<1.5×10^{−3}).

CH25H and INSIG2 variants
CH25H codes for cholesterol 25-hydroxylase, known to catalyse the formation of the oxysterol—25-hydroxycholesterol (25-HC) (9). The INSIG2 gene, which also exhibited an excess of novel functional variants in the FH cohort in comparison with the controls (p=3.7×10^{−3}) (table 1), has been demonstrated to regulate the activity of Sterol Regulatory Element-Binding Protein (SREBPs), a family of major lipid metabolism transcription factors, via direct binding of 25-HC. Thus, both genes, CH25H and INSIG2, are involved in the same pathway of cholesterol metabolism. There were three heterozygous variants found in CH25H, all confirmed by Sanger sequencing (see online supplementary figure S4), of which one leads to a formation of a premature stop codon at residue 81, predicted to have a damaging effect on the protein; the second affects a well-conserved residue across species, c.568G>A (p.V190I); and the third, c.716A>C (p.H239P), alters one of the crucial residues of the His Box 3 domain, known to play a crucial role, together with His Boxes 1 and 2, in the catalytic activity of CH25H. Two novel functional variants were found in the control cohort, both being non-synonymous (p.P197Q and p.C248G). The p.P197Q is located in a conserved region of the protein; however, it is predicted as tolerated/benign/neutral by SIFT/PolyPhen/Mutation Taster. The p.C248G variant affects a residue that is not conserved.

Sanger sequencing also confirmed two novel functional variants in the INSIG2 gene called in the cases, both non-synonymous changes (see online supplementary figure S5). A mutation prediction report generated by Project HOPE highlighted that the c.89T>C (p.I30T) variant will cause an empty space in the core of INSIG2 because of the size differences between the wild type Isoleucine and the smaller mutant—Threonine. The other variant, c.236C>T (p.T79M), located in the transmembrane domain of INSIG2, is predicted to have an effect on the hydrophobic interactions within the core of the protein or with the membrane lipids, because the mutant Methionine is more hydrophobic than the wild type Threonine. One rare missense variant was found in INSIG2 in the controls (p.D126N), which was predicted as tolerated/probably damaging/disease causing (by SIFT/PolyPhen/Mutation Taster).

DISCUSSION
In this study, we have identified 25 mutations in known FH genes (23 in LDLR and two in APOB), which were missed by the current screening protocol. Because the sequencing coverage of the PCSK9 gene was lower than for LDLR and APOB, we cannot rule out that there may have been undetected mutations in this gene also. This finding confirmed that LDLR locus is highly heterogeneous and mutations within this gene account for the majority of FH causes. The issue of genetic misdiagnosis and the need for an update of current screening methods have been previously discussed. In addition to the known FH mutations, we identified six novel APOB variants, distributed across different exons, in five patients, which included the recently examined p.R50W variant. The pathogenicity of these variants remains to be tested. Most of the current mutation screening strategies for FH are focused on a selected region of exon 26 of APOB, because of its established function; however, the whole exome sequencing enabled us to analyse the entire coding sequence of the gene, by which we found novel variants unique to the FH cohort.

Polygenic hypercholesterolaemia
The cumulative effect of common LDL-raising alleles in genes identified by GWAS was shown to be the likely cause of high LDL-C in a significant proportion (27%) of the examined patients. A gene score above the top decile for a healthy population cut-off (1.16) was also observed in two patients with considerably mild LDLR mutations, which demonstrates that common polymorphisms can contribute to the presentation of an individual carrying a mild effect FH mutation with LDL-C levels above the diagnostic threshold.

GWAS LDL-C genes
Since common variants in the LDL-C-associated GWAS genes were found to be important in the FH pathogenesis, we looked for evidence that rare variants in these genes were causing FH. Rare and novel functional variants in genes associated with LDL-C levels in the GWAS meta-analysis were not significantly over-represented in the FH cohort, when compared with controls. This suggests that rare variants that have a major effect on function in these genes known to have common LDL-C variants of modest effect are unlikely to be a common cause of FH.
only allowed for 125 subjects with FH to be included, and we calculated that, if we selected 125 singleton no-mutation patients with a clinical diagnosis of DFH, we would expect four to carry a shared mutated locus leading to the defective plasma clearance of LDL cholesterol. The power of the study is clearly dependent on the number of singletons included, with the idea that any identified candidate locus would be sequenced in the family members of the affected proband. While a group of singletons may be genetically heterogeneous, the use of the ‘burden’ analysis and not a single-variant test means that heterogeneity should not reduce power to detect a novel FH-causing gene. Another limitation is that we did not have lipid profile information for individuals in the control comparison cohort, only their rare disease phenotype status, which did not overlap with FH pathogenesis. The possibility that the control cohort includes FH-affected individuals was considered. Assuming that the prevalence of FH is 1/500, we would expect by chance to find ∼4 individuals in this cohort carrying an FH-causing mutation. We have analysed variants in LDLR, APOB and PCSK9 in the control cohort and identified three LDLR and two APOB mutations as incidental findings, which was similar to the expected FH frequency of one in 500. We have also allowed for this prevalence in the control comparison cohort by using a frequency cut-off of four novel gene functional variants in controls, in case any of the novel variants identified in FH cases were also present in the controls. A final limitation is that it is possible that some of the identified variants in the 18 genes in table 1 may be technical false positives, since only for the CH25H and INSIG2 genes were all variants confirmed by Sanger Sequencing. However, to be as certain as possible using bioinformatics that the variants we observed are not false positives, for all these variants we included a visual validation of the quality of calls performed using the Human Genome Polymerase Chain Reaction assay.

In summary, in 125 DFH unrelated patients without an identified mutation by conventional screening methods, analyses identified 25 disease-causing variants in already known FH loci, as well as six previously unreported APOB variants in five patients. LDL-C gene score analysis found that 31 (29 mutation or alteration of gene splicing. Also, it is possible that the LDL-C gene are genetic causes located outside of the protein coding region, covered regions could be missed. There is a possibility that there complications are technical false positives, since only for the CH25H and INSIG2 genes were all variants confirmed by Sanger Sequencing. However, to be as certain as possible using bioinformatics that the variants we observed are not false positives, for all these variants we included a visual validation of the quality of calls performed using the Human Genome Polymerase Chain Reaction assay.

Thus, overall, no major novel locus for FH was detected, with no gene having a functional variant in more than three patients. This suggests that the genetic cause of FH in these unexplained cases is likely to be very heterogeneous, which complicates the novel gene discovery and diagnostic process.

Author affiliations
1British Heart Foundation Laboratories, Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, the Rayne Building University College London, London, UK
2Department of Genetics, Environment and Evolution, UCL Genetics Institute, University College London, London, UK
3Department of Primary Care Health Sciences, NIHR School of Primary Care Research, University of Oxford, Oxford, UK
4Department of Cardiology, Imperial College Healthcare Services, Charing Cross Hospital, London, UK
5Department of Internal Medicine, University of Genova, Genoa, Italy
6Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
7Centre de Recherche Médicale de Jolimont, Haine St-Paul, Belgium
8Queens University Belfast & Regional Genetics Centre, Belfast Health and Social Care Trust/City Hospital Belfast BT9 7AB Northern Ireland UK
9Robarts Research Institute, London, Ontario, Canada
10OCDEM, Radcliffe Department of Medicine, University of Oxford, Churchill Hospital, Oxford, UK
11Cardiology Department, Hadassah Hebrew University Medical Center, Jerusalem, Israel
12Department of Medicine, Center for Research, Prevention and Treatment of Atherosclerosis, Hadassah Hebrew University Medical Centre, Jerusalem, Israel
13North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children, London, UK
14Consultant Lipidologist and Chemical Pathologist Director SAS Laboratory for Cardiac Biomarkers, Royal Free Hospital, London, UK
15Cardiovascular Trials Unit, University Department of Medicine, Central Manchester University Hospital NHS Foundation Trust, Manchester, UK
16Division of Laboratory Medicine, Department of Biochemistry, Royal Perth Hospital, Perth, Australia
17The University of Western Australia, Perth, Australia
18National Heart Research Centre, UK Medical Research Council, Oxford, UK

Acknowledgements This study makes use of data generated by the UK10K Consortium. A full list of the investigators who contributed to the generation of the data is available online (http://www.UK10k.org). Funding for UK10k was provided by the Wellcome Trust under award WT091310.

Collaborators
UK10K Consortium (http://www.uk10k.org).

Contributors All authors listed on the manuscript fulfill the criteria for authorship. Specific contributions are: MF: writing of the manuscript, data analysis. VP: data analysis, CNVs calling. KW: LDL-C gene score genotyping. RAW: sample preparation. HAWN, MS, SB, SC, OSD, CAJ, RAH, FK, RD, EL, NL, DRN, HS, FMVB: patient clinical diagnosis, selection and study samples providers. UK10K: exome sequencing and data production. SEH: data analysis, project supervision, guarantor of the publication.

Funding SEH holds a Chair funded by the British Heart Foundation, and SEH and RAW are supported by the BHF (PG08/008) and by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. MF is funded by an MRC CASE award with Gen-Probe Life Sciences, and VP is partially funded by a MRC research grant (G1001158). HAWN is a NIHR Senior Investigator.

Competing interests None.

Ethics approval Ethical Governance Framework UK10K. National Research Ethics Service, Cambridge 2 Research Committee (http://www.uk10k.org/ethics.html).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.

REFERENCES